UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i402-i403

2024

Link zum Volltext

Verfügbarkeit prüfen

DOP32 CD226+TIGITneg expression identifies pathogenic inflammatory CD4+ memory T cells in severe Crohn’s Disease patients, opening up opportunities for patient-tailored treatment strategies

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i130-i130

2024

Link zum Volltext

Verfügbarkeit prüfen

OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i004-i005

2022

Link zum Volltext

Verfügbarkeit prüfen

OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i13-i14

2023

Link zum Volltext

Verfügbarkeit prüfen

P347 New-onset autoimmune disorders, primarily psoriasis, in anti-TNF biologic exposed paediatric patients: the DEVELOP experience

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S276-S277

2019

Link zum Volltext

Verfügbarkeit prüfen

P382 Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S297-S298

2019

Link zum Volltext

Verfügbarkeit prüfen

P064 High intestinal Secretory Leukocyte Protease Inhibitor (SLPI) expression correlates with abundant neutrophilic inflammation and identifies Inflammatory Bowel Disease patients with a strong IL-17 response

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i232-i233

2023

Link zum Volltext

Verfügbarkeit prüfen

P021 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S139-S139

2021

Link zum Volltext

Verfügbarkeit prüfen

P045 TIGIT expression differentiates regulatory from inflammatory Th1 gut-homing effector CD4+ T cells in inflammatory bowel disease patients

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i161-i161

2022

Link zum Volltext

Verfügbarkeit prüfen

P069 Elevated adaptive immune responses to multiple Lachnospiraceae bacterial flagellins in therapy-naïve pediatric CD patients are associated with distinct immune pathology

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i235-i236

2023

Link zum Volltext

Verfügbarkeit prüfen

P061 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i171-i171

2022

Link zum Volltext

Verfügbarkeit prüfen

P012 Low frequencies of circulating inhibitory TIGIT+CD38+ effector T cells identify an immunologically distinct subgroup of pediatric patients with severe Crohn’s disease

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S134-S134

2021

Link zum Volltext

Verfügbarkeit prüfen

DOP67 First-line infliximab is cost-effective compared to conventional treatment in paediatric Crohn’s Disease – Results from the TISKids study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i111-i112

2022

Link zum Volltext

Verfügbarkeit prüfen

DOP69 Long-term outcome of infantile and very early onset IBD: A multi-center study from the IBD Porto group of ESPGHAN

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i112-i113

2022

Link zum Volltext

Verfügbarkeit prüfen

P398 Effect of Intravenous versus Oral Iron Therapy on Physical Fitness and Haemoglobin in Paediatric IBD Patients with Anaemia

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S407-S408

2021

Link zum Volltext

Verfügbarkeit prüfen

OP27 High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S020-S020

2019

Link zum Volltext

Verfügbarkeit prüfen

P-072: Growth improvement in adalimumab-treated paediatric patients with Crohn’s disease: data from IMAgINE 1

Journal of Crohn's and colitis, 2014-09, Vol.8, p.S420-S421

2014

Link zum Volltext

Verfügbarkeit prüfen

O-01: IL-10 receptor dependent signals regulate the generation and function of anti-inflammatory macrophages in mice and humans

Journal of Crohn's and colitis, 2014-09, Vol.8, p.S393-S393

2014

Link zum Volltext

Verfügbarkeit prüfen

15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry data

Journal of Crohn's and colitis, 2013-02, Vol.7, p.S7-S8

2013

Link zum Volltext

Verfügbarkeit prüfen

P436 Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry data

Journal of Crohn's and colitis, 2013-02, Vol.7, p.S184-S185

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

ThemaAntibodies, Monoclonal - Therapeutic Use

KollektionElsevier ScienceDirect Journals

KollektionOxford Journals 2020 Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Kollektion

Oxford University Press Full Collection 2022
(20)
Journals@Ovid Ovid Full Text
(20)
IngentaConnect
(20)
Elsevier ScienceDirect Journals Complete
(20)

Zeitschrift / Serie

Journal Of Crohn's And Colitis
(20)

Menü

Weitere Dienste

Einstellungen

P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients

DOP32 CD226+TIGITneg expression identifies pathogenic inflammatory CD4+ memory T cells in severe Crohn’s Disease patients, opening up opportunities for patient-tailored treatment strategies

OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial

OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial

P347 New-onset autoimmune disorders, primarily psoriasis, in anti-TNF biologic exposed paediatric patients: the DEVELOP experience

P382 Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience

P064 High intestinal Secretory Leukocyte Protease Inhibitor (SLPI) expression correlates with abundant neutrophilic inflammation and identifies Inflammatory Bowel Disease patients with a strong IL-17 response

P021 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course

P045 TIGIT expression differentiates regulatory from inflammatory Th1 gut-homing effector CD4+ T cells in inflammatory bowel disease patients

P069 Elevated adaptive immune responses to multiple Lachnospiraceae bacterial flagellins in therapy-naïve pediatric CD patients are associated with distinct immune pathology

P061 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course

P012 Low frequencies of circulating inhibitory TIGIT+CD38+ effector T cells identify an immunologically distinct subgroup of pediatric patients with severe Crohn’s disease

DOP67 First-line infliximab is cost-effective compared to conventional treatment in paediatric Crohn’s Disease – Results from the TISKids study

DOP69 Long-term outcome of infantile and very early onset IBD: A multi-center study from the IBD Porto group of ESPGHAN

P398 Effect of Intravenous versus Oral Iron Therapy on Physical Fitness and Haemoglobin in Paediatric IBD Patients with Anaemia

OP27 High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease

P-072: Growth improvement in adalimumab-treated paediatric patients with Crohn’s disease: data from IMAgINE 1

O-01: IL-10 receptor dependent signals regulate the generation and function of anti-inflammatory macrophages in mice and humans

15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry data

P436 Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry data

Aktive Filter

Suchergebnisse filtern